I think we're on the closer side of 66 than 80 seeing as we met our first interim a couple months late. That could've been for many reasons. But, either way, it would extend all estimates.
My question is, does it accelerate at this point? If the treatment was truly effective and led to the late triggering of events, it's likely that there will be a response multiplier. If the trial is ho-huming along as expected, I think we start seeing increased tumor progression in the control arm.
N'est-ce pas?
I don't know. The longer, the better.